CONTEXT
Most of chemotherapy drugs have serious toxicity side effects since they are not specifically targeting tumor cells but also normal cells. These drugs are however still widely used since they have good efficacy for cancer treatment. The vectorization of such drugs and the development of new galenic forms are therefore a major challenge for the pharmaceutical industry.
DESCRIPTION
A research team, specialized in lipoproteins, had the idea to use human lipoproteins to vectorize cytotoxic drugs while targeting specific cell types depending on the composition in lipoproteins of the vector and thus enabling better therapeutic efficacy and less toxicity. When LDLs are used as vector for the drug, an effect is only observed on cancer cells, whereas with HDLs vectors the effect seems to be only on macrophages. In both cases, the vectorization with such specific LDL or HDL lipoproteins increases treatment efficiency by more than 50% compared to non-vectorized cisplatin, as measured in animal studies.
COMPETITIVE ADVANTAGES
MARKETS & APPLICATIONS
Pharmaceutical – oncology :
- Drug vectorization
- Targeted drug delivery
- Toxicity or insolubility solution
DEVELOPMENT STAGE
Validated in vitro and in vivo with cisplatin
RESEARCH TEAM
Laboratory Lipids, Nutrition, Cancer University of Burgundy - INSERM
INTELLECTUAL PROPERTY
French patent application (May 31st, 2016) and PCT application (WO2017207897)
TARGET PARTNERSHIP
Patent licensing or co-development
CONTACT
Daniel KIRCHHERR
Business Development Manager
+33 (0)7 76 16 66 90
daniel.kirchherr@sayens.fr